FDA
-
-
-
-
-
-
-
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
-
-
-
-
-
-
-
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
-
-
-
-
-
-
-
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
-
-
-
-
-
-
-
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
-
-
-
-
-
-
-
Morgan Stanley on Biohaven (BHVN): 'The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2/3 data in major depressive disorder (MDD)'
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
329,980 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

